ATB Therapeutics
Manufacturing · Belgium · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Science Park Novalis 8, Aye, Wallonia, 6...Phone Number
+32 472227401Website
www.atbtherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About ATB Therapeutics
ATB Therapeutics has engineered a proprietary technology to manufacture a unique kind of immunotherapeutic designed to combine very high efficacy with unprecedent safety profile. ATB Therapeutics was funded in 2017 and aims to generate a pipeline of assets for hard-to-treat hematological and solid cancers. The company is now entering preclinical stage.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ATB Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if ATB Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at ATB Therapeutics
Funding: Get notified immidiatlly once ATB Therapeutics has new funding data
Click to see if ATB Therapeutics had a recent Job posting/layoffs
ATB Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when ATB Therapeutics launches new products
Check out if ATB Therapeutics is spiking on competitors!
Earning: See what the market has to say on ATB Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at ATB Therapeutics
Find 3 more new buyers
Company Profile Activity
Activity Insights
ATB Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ATB Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ATB Therapeutics.
ATB Therapeutics financials insights
Gather financial insights about ATB Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series A
$57.2M
ATB Therapeutics Tech Stack
A closer look at the technologies used by ATB Therapeutics
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Funding
Funding
ATB Therapeutics News & Media
ATB Therapeutics: Biologics Company Raises €54 Million (Series A) - Pulse 2.0
EQT Life Sciences announced that its LSP 7 fund has invested in ATB Therapeutics. The €54 million Series A funding round aims to accelerate the clinical development of a therapeutic antibody pipeline derived from its proprietary ATBioFarm platform. The funding was co-led by EQT Life Sciences and MRL Ventures Fund (a corporate venture arm of Merck), along with contributions from V-Bio, VIVES Partners, the Belgian sovereign fund SFPIM, Wallonie Entreprendre, Sambrinvest, and existing investors.EQT Life Sciences leads €54 Million Series A Financing of ATB Therapeutics
· Proceeds will fund clinical development of oncology and immunology therapeutics derived from innovative antibody payload platform · Mark Throsby, industry veteran and former CSO of Merus, joins as Executive Chair EQT Life Sciences is pleased to announce that its LSP 7 fund has invested in ATB Therapeutics. The €54 million Series A funding round is aimed at accelerating the clinical development of a groundbreaking therapeutic antibody pipeline derived from its proprietary ATBioFarm platform. Thatbtherapeutics Initiates Agreement With iBio CDMO to Manufacture Game-changer atbodies to Better Treat Cancer
MARCHE-EN-FAMENNE, Belgium--(BUSINESS WIRE)--atbtherapeutics, a pioneering biopharmaceutical company building an oncology pipeline using its antibody–toxin-bioengineered “atbody”, announces that it has entered a long-term manufacturing agreement with iBio CDMO, a global leader in plant-based biologics manufacturing located in the US. In this agreement, atbtherapeutics and iBio CDMO will work together for the industrialisation of the GMP manufacturing process of atbtherapeutics’ atbodies – game-
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ATB Therapeutics
Sign Up For FreeTo access detailed company insights
ATB Therapeutics has engineered a proprietary technology to manufacture a unique kind of immunotherapeutic designed to combine very high efficacy with unprecedent safety profile. ATB Therapeutics was funded in 2017 and aims to generate a pipeline of assets for hard-to-treat hematological and solid cancers. The company is now entering preclinical st... Read More
